{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+B&page=7", "query": { "intervention": "Dose B", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 6946, "total_pages": 695, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+B&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+B&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T15:19:19.382Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00782821", "title": "Randomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Kidney Transplantation" ], "interventions": [ { "name": "Rabbit Antithymocyte Globulin", "type": "DRUG" }, { "name": "Velcade", "type": "DRUG" }, { "name": "Rituxan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 40, "start_date": "2008-09", "completion_date": "2013-03", "has_results": true, "last_update_posted_date": "2016-01-20", "last_synced_at": "2026-10-19T15:19:19.382Z", "location_count": 2, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00782821" }, { "nct_id": "NCT00486759", "title": "A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "B-cell Lymphoma" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "CHOP", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 787, "start_date": "2007-07-26", "completion_date": "2011-11-30", "has_results": true, "last_update_posted_date": "2017-07-25", "last_synced_at": "2026-10-19T15:19:19.382Z", "location_count": 17, "location_summary": "La Jolla, California • Whittier, California • Aurora, Colorado + 14 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00486759" }, { "nct_id": "NCT03139370", "title": "Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "KITE-718", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "MAGE - A3/A6 Screening Test", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Kite, A Gilead Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2017-12-27", "completion_date": "2023-06-04", "has_results": false, "last_update_posted_date": "2023-08-25", "last_synced_at": "2026-10-19T15:19:19.382Z", "location_count": 12, "location_summary": "Gilbert, Arizona • Los Angeles, California • Sacramento, California + 7 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03139370" }, { "nct_id": "NCT07216105", "title": "FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer", "Colorectal Cancer", "Breast Cancer", "Ovarian Cancer", "Endometrial Carcinoma", "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "FT836", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 119, "start_date": "2025-11-04", "completion_date": "2030-01", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-10-19T15:19:19.382Z", "location_count": 5, "location_summary": "La Jolla, California • Los Angeles, California • Minneapolis, Minnesota + 2 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07216105" }, { "nct_id": "NCT02307851", "title": "Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "Quadrivalent VLP Vaccine", "type": "BIOLOGICAL" }, { "name": "Comparator TIV", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novavax", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 400, "start_date": "2014-11", "completion_date": "2015-06", "has_results": false, "last_update_posted_date": "2016-09-23", "last_synced_at": "2026-10-19T15:19:19.382Z", "location_count": 5, "location_summary": "Anaheim, California • Miami, Florida • Lenexa, Kansas + 2 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Lenexa", "state": "Kansas" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02307851" }, { "nct_id": "NCT06846320", "title": "Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Generalized Anxiety Disorder (GAD)" ], "interventions": [ { "name": "ABBV-932", "type": "DRUG" }, { "name": "Placebo for ABBV-932", "type": "DRUG" }, { "name": "Antidepressant Therapy (ADT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 315, "start_date": "2025-04-29", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-10-19T15:19:19.382Z", "location_count": 49, "location_summary": "Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 43 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Colton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06846320" }, { "nct_id": "NCT01211483", "title": "Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "NSCLC (Advanced Non-small Cell Lung Cancer)" ], "interventions": [ { "name": "U3-1287", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 222, "start_date": "2010-09", "completion_date": "2013-11-23", "has_results": true, "last_update_posted_date": "2021-06-16", "last_synced_at": "2026-10-19T15:19:19.382Z", "location_count": 14, "location_summary": "Glendale, Arizona • Scottsdale, Arizona • Anaheim, California + 11 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Encinitas", "state": "California" }, { "city": "La Verne", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01211483" }, { "nct_id": "NCT01731951", "title": "Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Myelofibrosis", "Secondary Myelofibrosis", "Myeloid Malignancies" ], "interventions": [ { "name": "Imetelstat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Geron Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2012-10-29", "completion_date": "2018-05-24", "has_results": true, "last_update_posted_date": "2021-09-21", "last_synced_at": "2026-10-19T15:19:19.382Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01731951" }, { "nct_id": "NCT01928576", "title": "Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer", "Epigenetic Therapy" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Entinostat", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "CC-486 300", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 143, "start_date": "2013-11-06", "completion_date": "2023-04-04", "has_results": true, "last_update_posted_date": "2024-05-03", "last_synced_at": "2026-10-19T15:19:19.382Z", "location_count": 5, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Baltimore, Maryland + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01928576" }, { "nct_id": "NCT06026397", "title": "A Sequential Single and Multiple Ascending Dose (SAD/MAD) Study of SK10 Powders in Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chemotherapy-induced Diarrhea" ], "interventions": [ { "name": "SK10", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Guangzhou Zhiyi Biotechnology Co., Ltd.", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 24, "start_date": "2023-08-01", "completion_date": "2024-02-11", "has_results": false, "last_update_posted_date": "2024-02-20", "last_synced_at": "2026-10-19T15:19:19.382Z", "location_count": 1, "location_summary": "Glendale, California", "locations": [ { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06026397" } ] }